177Lu-FAP-2286 Therapy in a Patient With Metastatic Rhabdoid Meningioma

Wan, Zibei; Wang, Wei; Chen, Yue; Zheng, Wenlu; Huang, Zhanwen

doi:10.1097/rlu.0000000000005258

Cited by 2 publications

(1 citation statement)

References 10 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a first-in-human trial in 11 patients, FAP-2286 demonstrated its utility as a therapeutic agent, with labeled 68 Ga used for diagnosis and 177 Lu for therapy ( 30 ). Recent case reports have also demonstrated the remarkable efficacy of 177 Lu-FAP-2286 against different types of epithelial cancer, offering a new treatment option to control disease progression and improve patient survival ( 39 – 42 ). However, further large-scale prospective studies on 68 Ga/ 177 Lu-FAP-2286 are needed to evaluate its safety, pharmacokinetics, dosimetry, and efficacy for patient management and integration.…”

Section: Discussionmentioning

confidence: 99%

Comparison of 68Ga-FAP-2286 and 18F-FDG PET/CT in the diagnosis of advanced lung cancer

Xiang,

Zhang,

Tan

et al. 2024

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

PurposeThe 68Ga/177Lu-FAP-2286 is a newly developed tumor imaging agent that shows potential for visualizing and treating tumor stroma. The objective of this research was to evaluate the effectiveness of 68Ga-FAP-2286 PET/CT and 18F-FDG PET/CT in diagnosing advanced lung cancer.MethodsIn this prospective study, patients with lung cancer who underwent 68Ga-FAP-2286 and 18F-FDG PET/CT examinations between September 2022 and June 2023 were analyzed. Lesion uptake was converted to SUVmax. A paired T-test was used to compare the SUVmax, and the number of positive lesions detected by the two methods was recorded.ResultsIn total, 31 participants (median age: 56 years) were assessed. The uptake of 68Ga-FAP-2286 was significantly higher than that of 18F-FDG in primary lesions (9.90 ± 5.61 vs. 6.09 ± 2.84, respectively, P < 0.001), lymph nodes (7.95 ± 2.75 vs. 5.55 ± 1.59, respectively, P=0.01), and bone metastases (7.74 ± 3.72 vs. 5.66 ± 3.55, respectively, P=0.04). Furthermore, the detection sensitivity of lymph nodes using 68Ga-FAP-2286 PET/CT was superior to that with 18F-FDG PET/CT [100% (137/137) vs. 78.8% (108/137), respectively], as well as for bone metastases [100% (384/384) vs. 68.5% (263/384), respectively]. However, the detection sensitivity for primary tumors using both modalities was comparable [100% (13/13) for both].ConclusionCompared to 18F-FDG PET/CT, 68Ga-FAP-2286 PET/CT demonstrated better lesion detection capabilities for lung cancer, particularly in lymph nodes and bone metastases, providing compelling imaging evidence for the efficacy of 177Lu-FAP-2286 treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of 68Ga-FAP-2286 and 18F-FDG PET/CT in the diagnosis of advanced lung cancer

Xiang,

Zhang,

Tan

et al. 2024

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

show abstract

Exploring the FAP-Targeted Therapeutics for Adrenocortical Carcinoma

Chopra,

Walia,

Kaur

et al. 2024

Clin Nucl Med

View full text Add to dashboard Cite

Metastatic or recurrent adrenocortical carcinoma is a potentially lethal malignancy, presenting significant challenges in disease management owing to absence of effective systemic treatments. Significantly diminished survival rates necessitate rapid identification of specific molecules for the development of targeted therapeutics. Fibroblast activation protein (FAP)–expressing cancer-associated fibroblasts have been a major breakthrough causing a paradigm shift in targeted theranostics focusing on the tumor microenvironment. The effectiveness of various FAP inhibitors (FAPis) and FAP targeting peptide has been extensively documented in diverse clinical investigations. We have evaluated 3 molecules, that is, DOTA.SA.FAPi (SA.FAPi), FAPi46, and FAP2286, as potential theranostic probes for adrenocortical carcinoma.

show abstract

177Lu-FAP-2286 Therapy in a Patient With Metastatic Rhabdoid Meningioma

Cited by 2 publications

References 10 publications

Comparison of 68Ga-FAP-2286 and 18F-FDG PET/CT in the diagnosis of advanced lung cancer

Comparison of 68Ga-FAP-2286 and 18F-FDG PET/CT in the diagnosis of advanced lung cancer

Exploring the FAP-Targeted Therapeutics for Adrenocortical Carcinoma

Contact Info

Product

Resources

About